The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Anti-miR-33 Therapy Does Not Alter the Progression of Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice
Open accessAbstract
Objective—: To determine the efficacy of long-term anti-miR-33 therapy on the progression of atherosclerosis in high-fat, high-cholesterol–fed Ldlr –/– mice. Methods and Results—: Ldlr –/– mice received saline, or control or anti-miR-33 oligonucleotides once a week for 14 weeks. The treatment was effective, as measured by reduced levels of hepatic miR-33 and increased hepatic expression of miR-33 targets. Analysis of plasma samples revealed an initial elevation in high-density lipoprotein cholesterol after 2 weeks of treatment that was not sustained by the end of the experiment. Additionally, we found a significant increase in circulating triglycerides in anti-miR-33–treated mice, compared with controls. Finally, examination of atheromata revealed no significant changes in the size or composition of lesions between the 3 groups. Conclusion—: Prolonged silencing of miR-33 fails to maintain elevated plasma high-density lipoprotein cholesterol and does not prevent the progression of atherosclerosis in Ldlr –/– mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, other similar studies did not observe any beneficial effects of anti-miR-33 therapy on atherogenesis (Marquart et al., 2013).”
From Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis (2017) · cites this paper as Marquart et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“Another study did not find reduced aortic lesions in anti-miR-33 treated mice (Marquart et al., 2013).”
From Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis (2017) · cites this paper as Marquart et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MiR-33 Contributes to the Regulation of Cholesterol Homeostasis
Rayner, K. J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M. L., Tamehiro, N., Fisher, E. A., Moore, K. J., & Fernández-Hernando, C. (2010) · Science · doi:10.1126/science.1189862 · Cited by 1,260
MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis
Najafi-Shoushtari, S. H., Kristo, F., Li, Y., Shioda, T., Cohen, D. E., Gerszten, R. E., & Näär, A. M. (2010) · Science · doi:10.1126/science.1189123 · Cited by 957
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
Rayner, K. J., Esau, C. C., Hussain, F. N., McDaniel, A. L., Marshall, S. M., van Gils, J. M., Ray, T. D., Sheedy, F. J., Goedeke, L., Liu, X., et al. (2011) · Nature · doi:10.1038/nature10486 · Cited by 706
Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690 · cited 3×
“increase HDL-c and accelerate the regression of atherosclerotic lesions in hyperlipidemic Ldlr mice switched to standard chow diet.(7) However, no reports are yet available”
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling
Dávalos, A., Goedeke, L., Smibert, P., Ramírez, C. M., Warrier, N. P., Andreo, U., Cirera-Salinas, D., Rayner, K., Suresh, U., Pastor-Pareja, J. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102281108 · Cited by 670
miR-33 links SREBP-2 induction to repression of sterol transporters
Marquart, T. J., Allen, R. M., Ory, D. S., & Baldán, Á. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005191107 · Cited by 562
Self-citationHorie, T., Ono, K., Horiguchi, M., Nishi, H., Nakamura, T., Nagao, K., Kinoshita, M., Kuwabara, Y., Marusawa, H., Iwanaga, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008499107 · Cited by 384
Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation*
Gerin, I., Clerbaux, L.-A., Haumont, O., Lanthier, N., Das, A. K., Burant, C. F., Leclercq, I. A., MacDougald, O. A., & Bommer, G. T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152090 · Cited by 382
Is it time to revise the HDL cholesterol hypothesis?
Rader, D. J., & Tall, A. R. (2012) · Nature Medicine · doi:10.1038/nm.2937 · Cited by 279
MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice
Horie, T., Baba, O., Kuwabara, Y., Chujo, Y., Watanabe, S., Kinoshita, M., Horiguchi, M., Nakamura, T., Chonabayashi, K., Hishizawa, M., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003376 · Cited by 220
Cited by
Sorted by citations
MicroRNA Regulation of Atherosclerosis
Feinberg, M. W., & Moore, K. J. (2016) · Circulation Research · doi:10.1161/circresaha.115.306300 · Cited by 638
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
Ouimet, M., Ediriweera, H. N., Gundra, U. M., Sheedy, F. J., Ramkhelawon, B., Hutchison, S. B., Rinehold, K., van Solingen, C., Fullerton, M. D., Cecchini, K., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81676 · Cited by 394
Transcriptional Control of Hepatic Lipid Metabolism by SREBP and ChREBP
Xu, X., So, J., Park, J., & Lee, A. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358523 · Cited by 321
Role of Flow-Sensitive microRNAs in Endothelial Dysfunction and Atherosclerosis
Kumar, S., Kim, C. W., Simmons, R. D., & Jo, H. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303425 · Cited by 274
MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice
Horie, T., Nishino, T., Baba, O., Kuwabara, Y., Nakao, T., Nishiga, M., Usami, S., Izuhara, M., Sowa, N., Yahagi, N., et al. (2013) · Nature Communications · doi:10.1038/ncomms3883 · Cited by 230
Non-coding RNAs in cardiovascular cell biology and atherosclerosis
Fasolo, F., Gregoli, K. D., Mäegdefessel, L., & Johnson, J. L. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz203 · Cited by 203
Rotllan, N., Ramírez, C. M., Aryal, B., Esau, C. C., & Fernández-Hernando, C. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301732 · Cited by 174
Vallim, T. Q. D. A., Tarling, E. J., Kim, T., Civelek, M., Baldán, Á., Esau, C., & Edwards, P. A. (2013) · Circulation Research · doi:10.1161/circresaha.112.300648 · Cited by 171
Self-citationLu, H. S., & Daugherty, A. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305380 · Cited by 171
miRNAs in atherosclerotic plaque initiation, progression, and rupture
Andreou, I., Sun, X., Stone, P. H., Edelman, E. R., & Feinberg, M. W. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.02.003 · Cited by 155
MicroRNAs in the Pathobiology and Therapy of Atherosclerosis
Laffont, B., & Rayner, K. J. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.01.001 · Cited by 153
Goedeke, L., Salerno, A., Ramírez, C. M., Guo, L., Allen, R. M., Yin, X., Langley, S. R., Esau, C., Wanschel, A., Fisher, E. A., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404046 · Cited by 145
Madrigal‐Matute, J., Rotllán, N., Aranda, J. F., & Fernandez-Hernando, C. F. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0322-z · Cited by 145
Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis
Price, N. L., Rotllan, N., Canfrán-Duque, A., Zhang, X., Pati, P., Arias, N., Moen, J., Mayr, M., Ford, D. A., Baldán, Á., et al. (2017) · Cell reports · doi:10.1016/j.celrep.2017.10.023 · Cited by 129
Self-citationLiver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?
Willeit, P., Skroblin, P., Kiechl, S. J., Fernandez-Hernando, C. F., & Mayr, M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw146 · Cited by 128
Rottiers, V., Obad, S., Petri, A., McGarrah, R., Lindholm, M. W., Black, J. C., Sinha, S., Goody, R. J., Lawrence, M. S., deLemos, A. S., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006840 · Cited by 121
MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis
Schober, A., Nazari-Jahantigh, M., & Weber, C. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.38 · Cited by 114
microRNAs in lipoprotein metabolism and cardiometabolic disorders
Rotllan, N., Price, N., Pati, P., Goedeke, L., & Fernández-Hernando, C. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.025 · Cited by 100
microRNA Therapeutics in Cardiovascular Disease Models
Dangwal, S., & Thum, T. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135957 · Cited by 112
Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis
Novák, J., Olejníčková, V., Tkáčová, N., & Santulli, G. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-22380-3_5 · Cited by 95
Distel, E., Barrett, T. J., Chung, K., Girgis, N. M., Parathath, S., Essau, C. C., Murphy, A. J., Moore, K. J., & Fisher, E. A. A. (2014) · Circulation Research · doi:10.1161/circresaha.115.304164 · Cited by 104
Javadifar, A., Rastgoo, S., Banach, M., Jamialahmadi, T., Johnston, T. P., & Sahebkar, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052529 · Cited by 108
Wu, Z., He, Y., Li, D., Fang, X., Shang, T., Zhang, H., & Zheng, X. (2017) · PubMed Central · Cited by 97
miR-33-5p, a novel mechano-sensitive microRNA promotes osteoblast differentiation by targeting Hmga2
Wang, H., Sun, Z., Wang, Y., Hu, Z., Zhou, H., Zhang, L., Hong, B., Zhang, S., & Cao, X. (2016) · Scientific Reports · doi:10.1038/srep23170 · Cited by 96
Small Things Matter: Relevance of MicroRNAs in Cardiovascular Disease
Peters, L. J. F., Biessen, E. A. L., Hohl, M., Weber, C., van der Vorst, E. P. C., & Santovito, D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00793 · Cited by 101
MicroRNA Control of High-Density Lipoprotein Metabolism and Function
Rayner, K. J., & Moore, K. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.300645 · Cited by 91
Goedeke, L., Rotllan, N., Ramírez, C. M., Aranda, J. F., Canfrán-Duque, A., Araldi, E., Fernández-Hernando, A., Langhi, C., de Cabo, R., Baldán, Á., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.033 · Cited by 65
Self-citationKarunakaran, D., Richards, L. M., Geoffrion, M., Barrette, D., Gotfrit, R., Harper, M., & Rayner, K. J. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306404 · Cited by 67
MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases
Aranda, J. F., Madrigal‐Matute, J., Rotllán, N., & Fernandez-Hernando, C. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.014 · Cited by 67
Liao, B., Chen, R., Lin, F., Mai, A., Chen, J., Li, H., Xu, Z., & Dong, S. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26448 · Cited by 65
Micro-RNAs and High-Density Lipoprotein Metabolism
Canfrán‐Duque, A., Lin, C., Goedeke, L., Suárez, Y., & Fernandez-Hernando, C. F. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307028 · Cited by 64
MicroRNAs in obesity-associated disorders
Abente, E. J., Subramanian, M., Ramachandran, V., & Najafi-Shoushtari, S. H. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.09.018 · Cited by 63
The role of miRNAs in cardiovascular disease risk factors
Buie, J. N. J., Goodwin, A. J., IV, Cook, J. A., Halushka, P. V., & Fan, H. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.09.067 · Cited by 63
Anti–miR-148a regulates platelet FcγRIIA signaling and decreases thrombosis in vivo in mice
Zhou, Y., Abraham, S., André, P., Edelstein, L. C., Shaw, C. A., Dangelmaier, C., Tsygankov, A. Y., Kunapuli, S. P., Bray, P. F., & McKenzie, S. E. (2015) · Blood · doi:10.1182/blood-2015-02-631135 · Cited by 59
Canfrán‐Duque, A., Ramírez, C. M., Goedeke, L., Lin, C., & Fernandez-Hernando, C. F. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu140 · Cited by 59
Elucidating the contributory role of microRNA to cardiovascular diseases (a review)
Johnson, J. L. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.10.010 · Cited by 60
Eyeballing cholesterol efflux and macrophage function in disease pathogenesis
Sène, A., & Apte, R. S. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.10.007 · Cited by 56
Relevance of microRNA in metabolic diseases
Price, N. L., Ramírez, C. M., & Fernandez-Hernando, C. F. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.937522 · Cited by 55
MicroRNAs and metabolic disorders – where are we heading?
Śliwińska, A., Kasińska, M., & Drzewoski, J. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.65229 · Cited by 55
Posttranscriptional regulation of lipid metabolism by non-coding RNAs and RNA binding proteins
Singh, A. K., Aryal, B. K., Zhang, X., Fan, Y., Price, N. L., Suárez, Y., & Fernandez-Hernando, C. F. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.11.026 · Cited by 55
Non-coding RNAs in lipid metabolism
Zhang, X., Price, N. L., & Fernandez-Hernando, C. F. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.06.011 · Cited by 54
Stamatikos, A., Knight, E., Vojtech, L. N., Bi, L., Wacker, B. K., Tang, C., & Dichek, D. A. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.245 · Cited by 54
Huang, K., Bao, H., Yan, Z., Wang, L., Zhang, P., Yao, Q., Shi, Q., Chen, X., Wang, K., Shen, B., et al. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvw257 · Cited by 52
Novák, J., Vašků, J. B., Kára, T., & Novák, M. (2014) · Mediators of Inflammation · doi:10.1155/2014/275867 · Cited by 53
HDL and microRNA therapeutics in cardiovascular disease
Michell, D. L., & Vickers, K. C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.001 · Cited by 45
Small but smart: MicroRNAs orchestrate atherosclerosis development and progression
Santovito, D., Egea, V., & Weber, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2015.12.013 · Cited by 45
The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic Diseases
Sethupathy, P. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0745-3 · Cited by 44
MicroRNA regulation of cholesterol metabolism
Citrin, K. M., Fernandez-Hernando, C. F., & Suárez, Y. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14566 · Cited by 45
MicroRNAs as therapeutic targets in atherosclerosis
Loyer, X., Mallat, Z., Boulanger, C. M., & Tedgui, A. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.989835 · Cited by 43
Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33
Allen, R. M., Marquart, T. J., Jesse, J. J., & Baldán, Á. (2014) · Circulation Research · doi:10.1161/circresaha.115.303100 · Cited by 38
Self-citationmiR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches
Price, N. L., Goedeke, L., Suárez, Y., & Fernández‐Hernando, C. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012606 · Cited by 36
“…regulates intracellular cholesterol trafficking by targeting a number of different factors, including NPC1, OSBPL6, and NSF (Rayner et al, 2010; Marquart et al, 2013; CD 4+ T CELLS Srebp2/miR-33 ALDH1A2 CROT AMPK ABCA1ABCG1 NPC1 TLR4 NFκB IL1β miR-33 APOA1HDL INNATE INMUNITY Foxp3+…”
BackgroundMicroRNA-33a/b in Lipid Metabolism
Ono, K., Horie, T., Nishino, T., Baba, O., Kuwabara, Y., Yokode, M., Kita, T., & Kimura, T. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-1252 · Cited by 34
ATP-binding cassette transporter A1
Eck, M. V. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000088 · Cited by 35
MicroRNAs and Lipoprotein Metabolism
Horie, T., Baba, O., Kuwabara, Y., Yokode, M., Kita, T., Kimura, T., & Ono, K. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.20859 · Cited by 29
Macrophage miRNAs in atherosclerosis
Karunakaran, D., & Rayner, K. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.02.006 · Cited by 29
Coenzyme Q10 Increases Cholesterol Efflux and Inhibits Atherosclerosis Through MicroRNAs
Allen, R. M., & Vickers, K. C. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303741 · Cited by 29
Vahdat‐Lasemi, F., Mahjoubin‐Tehran, M., Aghaee‐Bakhtiari, S. H., Jalili, A., Jaafari, M. R., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.04.007 · Cited by 24
A big role for small RNAs in HDL homeostasis
Ouimet, M. I., & Moore, K. J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036327 · Cited by 21
MOVAS Cells: A Versatile Cell Line for Studying Vascular Smooth Muscle Cell Cholesterol Metabolism
Esobi, I. C., Barksdale, C., Heard‐Tate, C., Powell, R. R., Bruce, T. F., & Stamatikos, A. (2021) · Lipids · doi:10.1002/lipd.12303 · Cited by 23
MicroRNAs and Cardiovascular Disease
Fernandez-Hernando, C. F., & Baldán, Á. (2013) · Current Genetic Medicine Reports · doi:10.1007/s40142-013-0008-4 · Cited by 19
Self-citationCuadrado, I., Saura, M., Castejón, B., Martin, A. M., Herruzo, I., Balatsos, N. A. A., Zamorano, J. L., & Zaragoza, C. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.5 · Cited by 19
Mallat, Z. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309730 · Cited by 19
MicroRNA-Management of Lipoprotein Homeostasis
Sun, X., & Feinberg, M. W. (2014) · Circulation Research · doi:10.1161/circresaha.114.304228 · Cited by 19
Harnessing the Therapeutic Potential of MicroRNAs for Cardiovascular Disease
Calway, T., & Kim, G. H. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414552902 · Cited by 17
Kowara, M., Borodzicz-Jażdżyk, S., Rybak, K., Kubik, M., & Cudnoch‐Jędrzejewska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115718 · Cited by 17
miRNAs and High-Density Lipoprotein metabolism
Baldán, Á., & Vallim, T. Q. D. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.01.021 · Cited by 18
Self-citationDevelopment of Antisense Drugs for Dyslipidemia
Yamamoto, T., Wada, F., & Harada‐Shiba, M. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16001 · Cited by 17
Anti-atherosclerosis or No Anti-atherosclerosis
Näär, A. M. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.301021 · Cited by 17
Esobi, I. C., Oladosu, O., Echesabal-Chen, J., Powell, R. R., Bruce, T. F., & Stamatikos, A. (2023) · Journal of Lipids · doi:10.1155/2023/8241899 · Cited by 19
Zhang, Y., Ma, X., Li, X., Zhang, T., Qin, M., & Ren, L. (2018) · BioMed Research International · doi:10.1155/2018/9424186 · Cited by 16
Inhibition of microRNA-33b in humanized mice ameliorates nonalcoholic steatohepatitis
Miyagawa, S., Horie, T., Nishino, T., Koyama, S., Watanabe, T., Baba, O., Yamasaki, T., Sowa, N., Otani, C., Matsushita, K., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202301902 · Cited by 14
Liver-specific microRNA-185 knockout promotes cholesterol dysregulation in mice
Chen, C., Matye, D. J., Wang, Y., & Li, T. (2020) · Liver Research · doi:10.1016/j.livres.2020.09.001 · Cited by 14
Vladimirov, S. S., Tomasevic, M., Popov, N., Munjas, J., de Gonzalo‐Calvo, D., & Sopić, M. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.005 · Cited by 14
Evolving targets for lipid‐modifying therapy
Do, R. Q., Nicholls, S. J., & Schwartz, G. G. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404000 · Cited by 13
Baba, O., Horie, T., Nakao, T., Hakuno, D., Nakashima, Y., Nishi, H., Kuwabara, Y., Nishiga, M., Nishino, T., Ide, Y., et al. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00604-17 · Cited by 12
Kaur, K. K. (2015) · Journal of Health & Medical Informatics · doi:10.4172/2157-7420.1000184 · Cited by 10
Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions
Guo, Y., Luo, F., Yi, Y., & Xu, D. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0381-6 · Cited by 11
Very low HDL levels: clinical assessment and management
Bonilha, I., Luchiari, B., Nadruz, W., & Sposito, A. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000585 · Cited by 12
Antisense Oligonucleotides, microRNAs, and Antibodies
Dávalos, A., & Chroni, A. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_22 · Cited by 10
Truths and controversies concerning the role of miRNAs in atherosclerosis and lipid metabolism
Baldán, Á., & Fernandez-Hernando, C. F. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000358 · Cited by 9
Self-citationShi, X., Pan, S., Li, L., Li, Y., Ma, W., Wang, H., Xu, C., Li, L., & Wang, D. (2020) · Aging · doi:10.18632/aging.103079 · Cited by 7
Oladosu, O., Chin, E., Barksdale, C., Powell, R. R., Bruce, T., & Stamatikos, A. D. (2024) · Pathophysiology · doi:10.3390/pathophysiology31010009 · Cited by 8
Quest for new biomarkers in atherosclerosis.
Cho, Y., & Baldán, Á. (2013) · Europe PMC (PubMed Central) · Cited by 8
Self-citationHemostatic disorders of the menopausal period: the role of microRNA
Stachowiak, G., Zając, A. E., Nowak, M., Stetkiewicz, T., & Wilczyński, J. R. (2015) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2015.52155 · Cited by 7
Noncoding RNAs in vascular inflammation and atherosclerosis
Cochain, C., & Zernecke, A. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000108 · Cited by 7
Epigenetic factors in atherogenesis: microRNA
Smirnova, A. V., Sukhorukov, V. N., Карагодин, В. П., & Orekhov, A. N. (2016) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20166202134 · Cited by 8
Huang, K., Pokhrel, A., Echesabal-Chen, J., Scott, J., Bruce, T., Jo, H., & Stamatikos, A. D. (2025) · Medicina · doi:10.3390/medicina61020329 · Cited by 5
Scherrer, D. Z., Zago, V. H. D. S., Parra, E. S., Avansini, S. H., Panzoldo, N. B., Alexandre, F., Baracat, J., Nakandakare, E. R., Quintão, E. C. R., & de Faria, E. C. (2015) · Gene · doi:10.1016/j.gene.2015.05.074 · Cited by 4
Noncoding RNAs in Platelet Biology
Edelstein, L. C., & Bray, P. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_18 · Cited by 3
Ekici, S., & Özmen, Ö. (2020) · Journal of Equine Veterinary Science · doi:10.1016/j.jevs.2020.103218 · Cited by 2
Montaño-Samaniego, M., Sánchez-Cedillo, J., Lucas-González, A., Bravo‐Estupiñan, D. M., Alarcón-Hernández, E., Rivera-Gutiérrez, S., Balderas-López, J. A., & Ibáñez-Hernández, M. Á. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45090445 · Cited by 3
Nesan, D., & Ng, D. S. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.937523 · Cited by 2
MicroRNA Regulation of HDL Homeostasis
Sun, X., & Feinberg, M. W. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00010-0 · Cited by 2
Noncoding RNAs in Cholesterol Metabolism and Atherosclerosis
Price, N. L., & Fernandez-Hernando, C. F. (2017) · Cardiac and vascular biology · doi:10.1007/978-3-319-52945-5_2 · Cited by 2
MicroRNAs and Cardiovascular Diseases
Henderson, J. M., Farina, F. M., & Santovito, D. (2024) · Epigenetics and human health · doi:10.1007/978-3-031-64788-8_9 · Cited by 1
MicroRNAs in the Pathogenesis, Diagnosis, and Treatment of Liver Disease
Madison, B., & Kerr, T. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800553-8.00004-4 · Cited by 1
Therapies Targeting HDLc Levels and HDL Function
Vitali, C., & Cuchel, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00012-4 · Cited by 1
In vitro veritas: 90 years of biochemistry at Saint Louis University.
Eissenberg, J. C., & Di Cera, E. (2013) · Europe PMC (PubMed Central)
Role of microRNA-21 in atherogenesis.
Hamed-Berair, R. E. (2016) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2431
Metadata
- Authors
- Marquart, T. J., Wu, J., Lusis, A. J., & Baldán, Á.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2013-03
- Volume
- 33
- Issue
- 3
- Pages
- 455-458
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- PMC
- PMC3587119
- OpenAlex
- W2169384530
- Cited by
- 110
- References
- 14
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 14 · 2016: 18 · 2015: 15 · 2014: 18 · 2013: 16
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Saint Louis University
- National Heart, Lung, and Blood Institute (HL030568, HL095154, P01HL030568, R01HL095154, HL107794, R01HL107794)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- miR-33, atherosclerosis progression, LDL receptor-deficient mice, HDL cholesterol, high-fat high-cholesterol diet, microRNA silencing
- MeSH terms
- Animals, Aorta, Aortic Diseases, Cholesterol, Dietary, Disease Models, Animal, Cholesterol, HDL, Liver, Male, Receptors, LDL, Time Factors, Triglycerides, Biomarkers, Down-Regulation, Oligonucleotides, Antisense, Mice, Knockout, Disease Progression, MicroRNAs, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
